Mutational Testing

Collaborative Effort Produces Position Paper on Need for Advanced Biomarker Testing

The Life Raft Group was recently part of team of authors on a collaborative position paper entitled 'Undetected KIT and PDGFRA mutations: an under-recognised cause of gastrointestinal stromal tumours (GISTs) incorrectly classified as wild-type published' in Pathology: The Journal of the Royal College of Pathologists of Australia.

By |2022-08-15T16:05:39-04:00August 15th, 2022|Mutational Testing, News, Research|

The Value of Biomarker Testing: Case Studies Across Multiple Institutions

In this webinar, there were case study presentations from three top sarcoma institutions that demonstrate the value of biomarker testing. A Question & Answer session followed the presentations.

By |2022-02-08T12:01:53-05:00January 12th, 2022|Mutational Testing, Webcast|

Tissue Testing Project

The Life Raft Group (LRG) is providing you with this information to let you know that comprehensive genomic profiling, also known as biomarker testing or molecular testing, is a crucial step in understanding the genomic factors that play a role in a GIST diagnosis. Bayer Pharmaceuticals, in partnership with The Life Raft Group (LRG), has extended a research collaboration to broaden access to comprehensive genomic testing (CGT) for Gastrointestinal Stromal Tumor (GIST) patients.

By |2021-11-04T10:18:38-04:00October 27th, 2021|Mutational Testing, News|
Go to Top